Febrile seizures (FSs) are the most common form of childhood seizures. Determining the role of trace elements in the pathophysiology of FSs will contribute to the management of FSs by pediatricians. This study aimed to investigate the effects of zinc and selenium on the nervous system and how they may influence the risk of FSs. In this case-control study, there were 60 children in the simple FS group and 40 children in the complex FS group. The control groups comprised 50 children with fever but without seizures and 50 healthy children. Blood samples were collected within the first hour after FS. Zinc and selenium levels were significantly lower in children with fever but without seizures versus healthy children (p<0.001). Serum zinc levels were lower in children with FSs (simple and complex FSs) than in healthy children (p<0.001) but higher than in children with fever but without seizures (p0.05). Serum zinc levels are significantly decreased during infection, whereas they show a statistically significant increase within the first hour after FS activity. This indicates that the body secretes zinc during FSs to restore homeostasis, reduce oxidative stress, and increase the seizure threshold. Therefore, zinc supplementation during febrile periods may effectively prevent FSs in high-risk children.
Objective: The aim of this study is to evaluate the prognostic factors in a single-center pediatric cohort with autoimmune encephalitis. Materials and Methods: The study group consisted of 23 pediatric autoimmune encephalitis patients (seropositive autoimmune encephalitis: 15, seronegative autoimmune encephalitis: 8). Five group prognostic parameters were evaluated: clinical manifestations, elect roenc ephal ograp hy features, magnetic resonance imaging characteristics, biomarkers, and treatment modalities. Three scoring models were applied: the Antibody Prevalence in Epilepsy and Response to Immunotherapy in Epilepsy for predicting autoimmune-related epilepsy in the whole cohort and the anti-N-methyl-d-aspartate receptor Encephalitis 1-Year Functional Status score for overall outcome in patients with anti-N-methyl-d-aspartate receptor encephalitis. Results: The initial clinical spectrum of the disease was similar in the seronegative and seropositive groups. Almost half of the patients (48%) recovered without any complications with first-line immunotherapy. The patients with movement disorders in the acute phase of the disease needed more likely second-line immunotherapy (P = .039). The presence of status epilepticus at admission was significantly associated with adverse outcomes and the development of autoimmune-related epilepsy (P = .019). Autoimmune-related epilepsy was defined in an equal proportion of patients (91.5%) with 2 immune epilepsy scores (Antibody Prevalence in Epilepsy and Response to Immunotherapy in Epilepsy). The N-methyl-d-aspartate receptor Encephalitis 1-Year Functional Status score and the modified Rankin score assessed for the first-year prognosis were strongly correlated among the patients with anti-N-methyl-d-aspartate receptor encephalitis (P = .03, Spearmen’s rho = 0.751). Conclusions: The presence of status epilepticus was the most important prognostic factor in the patients with the adverse outcome. The studied scoring models (Anti-N-methyl-d-aspartate receptor Encephalitis 1-Year Functional Status, Antibody Prevalence in Epilepsy, and Response to Immunotherapy in Epilepsy) have also been proven to be applicable to the pediatric age group for predicting overall outcome and autoimmune-related epilepsy. Cite this article as: Kanmaz S, Yılmaz S, Toprak DE, et al. Assessment of prognostic factors and validity of scoring models in childhood autoimmune encephalitis. Turk Arch Pediatr. 2023;58(2):142-153.
To evaluate the predictive value of the Erasmus Guillain-Barré syndrome (GBS) Respiratory Insufficiency Score (EGRIS) and the modified Erasmus GBS Outcome Score (mEGOS) for outcome in a pediatric cohort. The study group consisted of 32 GBS patients (n = 9 with axonal form, 28.1%) who received standard intravenous immunoglobulin therapy. The unfavorable outcome was defined as the inability to walk independently (with GBS disability score ≥3) at 6 months. Receiver operating characteristic (ROC) curve analyses were performed using both scoring systems to evaluate their predictive accuracy for early outcomes (need for mechanical ventilation and intensive care unit [ICU] admission) and for late motor outcome at 6 months. EGRIS yielded a strong accuracy (area under the curve [AUC] of 0.96 (95% CI: 0.85-1.00; cutoff ≥ 5) for predicting the need for mechanical ventilation and an AUC of 0.81 (95% CI: 0.63-1.00) for predicting ICU admission. The mEGOS score calculated at admission was significantly higher in the axonal subgroup ( P = .011). The mEGOS demonstrated strong predictive ability for ICU admission at presentation (AUC = 0.89; 95% CI: 0.74-1.00; cutoff ≥ 4). However, both EGRIS and mEGOS exhibited limited discriminative ability in identifying patients with mild neurologic disability at 6 months (AUC < 0.70). The EGRIS and mEGOS demonstrated strong predictive accuracy for early outcomes and limited discriminative ability for late motor outcomes. We considered that both scoring systems should be integrated into pediatric-specific prognostic frameworks at the bedside of GBS patients with electroclinical subtypes.